Is Targovax going to be the next big game changer in the Immuno-Oncology field?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Is Targovax going to be the next big game changer in the Immuno-Oncology field?
Released on: October 14, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Targovax and Oncos Therapetics have recently joined forces to provide a combination treatment in the Immuno-Oncology field.
  • Summary
  • Transcript
  • Participants
  • Company
Targovax and Oncos Therapetics have recently joined forces to provide a combination treatment in the Immuno-Oncology field. Targovax brings with it a clinical stage peptide vaccine and Oncos Therapeutics brings a clinical stage oncolytic virus. Together as a merged company, named Targovax, they hope to provide a game changing combination treatment in the exciting Immuno-Oncology field. Magnus Jaderberg, Chief Medical Officer of Targovax talks with Adrian Dawkes of PharmaVentures.
Targovax and Oncos Therapetics have recently joined forces to provide a combination treatment in the Immuno-Oncology field. Targovax brings with it a clinical stage peptide vaccine and Oncos Therapeutics brings a clinical stage oncolytic virus. Together as a merged company, named Targovax, they hope to provide a game changing combination treatment in the exciting Immuno-Oncology field. Magnus Jaderberg, Chief Medical Officer of Targovax talks with Adrian Dawkes of PharmaVentures.
Magnus Jaderberg is a A pharmaceutical physician with 25+ years in various R&D functions including clinical research, medical affairs, pharmacovigilance, strategic product development, health economics and general management. Experienced in all phases of clinical research including clinical pharmacology, dose finding, registration, post-launch product differentiation and surveillance. His immunotherapy expertise includes several compounds including Yervoy (ipilimumab). Prior to joining Oncos, Magnus held roles at national, European and global level at GSK, Pharmacia, Wyeth and most recently as Chief Medical Officer, Bristol Myers Squibb (Europe). Qualified in medicine at Karolinska Institute, Stockholm, Sweden, and is a fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom, and honorary lecturer in drug development at King’s College.
Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapies for cancer patients. A leader in the immuno-oncology field born out of the merger in July 2015 of Targovax and Oncos Therapeutics, Targovax is headquartered in Oslo with offices also in Helsinki. The new company is developing two complementary and highly targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Both treatment approaches harness the patient’s own immune system to fight the cancer.